Tag: Editas Medicine

Browse exclusive Tags!

FDA Grants RMAT Designation to Editas Medicine’s EDIT-301 for Severe Sickle Cell Disease, US

The FDA grants RMAT designation to Editas Medicine's EDIT-301 for severe sickle cell disease. Learn about the potential life-changing benefits of this innovative gene editing medicine.

Editas Medicine Appoints Linda C. Burkly as EVP and Chief Scientific Officer

Editas Medicine appoints Dr. Linda C. Burkly as EVP and Chief Scientific Officer to lead drug discovery team and advance gene editing therapies.

Popular

FDA Grants RMAT Designation to Editas Medicine’s EDIT-301 for Severe Sickle Cell Disease, US

The FDA grants RMAT designation to Editas Medicine's EDIT-301 for severe sickle cell disease. Learn about the potential life-changing benefits of this innovative gene editing medicine.

Subscribe

spot_imgspot_img